Man Group plc Has $12.51 Million Holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Man Group plc decreased its position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 9.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 297,394 shares of the biopharmaceutical company's stock after selling 29,809 shares during the period. Man Group plc owned 0.32% of Ultragenyx Pharmaceutical worth $12,511,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 259.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 683 shares of the biopharmaceutical company's stock valued at $29,000 after buying an additional 493 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new position in Ultragenyx Pharmaceutical in the fourth quarter worth approximately $35,000. Human Investing LLC bought a new position in Ultragenyx Pharmaceutical during the fourth quarter valued at approximately $42,000. Van ECK Associates Corp lifted its stake in Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. Van ECK Associates Corp now owns 1,760 shares of the biopharmaceutical company's stock valued at $74,000 after acquiring an additional 273 shares during the last quarter. Finally, Quarry LP bought a new stake in Ultragenyx Pharmaceutical in the fourth quarter worth approximately $84,000. Hedge funds and other institutional investors own 97.67% of the company's stock.

Insiders Place Their Bets

In other news, EVP Thomas Richard Kassberg sold 6,028 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $42.10, for a total value of $253,778.80. Following the sale, the executive vice president now owns 265,238 shares in the company, valued at approximately $11,166,519.80. The trade was a 2.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider John Richard Pinion sold 14,439 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $42.10, for a total transaction of $607,881.90. Following the transaction, the insider now directly owns 107,766 shares of the company's stock, valued at $4,536,948.60. This represents a 11.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 125,405 shares of company stock worth $5,285,169 over the last 90 days. Corporate insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Price Performance

RARE stock traded up $0.15 on Friday, reaching $35.66. 124,365 shares of the company were exchanged, compared to its average volume of 822,768. The firm has a market capitalization of $3.37 billion, a PE ratio of -5.63 and a beta of 0.34. Ultragenyx Pharmaceutical Inc. has a 12 month low of $29.59 and a 12 month high of $60.37. The stock's fifty day moving average price is $36.11 and its 200 day moving average price is $41.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) earnings per share for the quarter, missing the consensus estimate of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $139.29 million during the quarter, compared to the consensus estimate of $145.98 million. During the same quarter in the previous year, the business posted ($2.03) EPS. The firm's quarterly revenue was up 28.0% on a year-over-year basis. As a group, research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently weighed in on RARE. HC Wainwright restated a "buy" rating and set a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Morgan Stanley boosted their price target on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a research report on Friday, May 9th. Cantor Fitzgerald reissued an "overweight" rating and set a $118.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Canaccord Genuity Group raised their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the company a "buy" rating in a research note on Tuesday, February 18th. Finally, JPMorgan Chase & Co. upped their target price on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the stock an "overweight" rating in a research report on Thursday, March 27th. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $90.93.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.